Ahmed Zaghloul – CEO, October Pharma, Egypt
Ahmed Zaghloul, CEO of October Pharma, stresses the need for better infrastructure for biosimilars in Egypt to stay competitive on a global level. He also highlights October Pharma’s ambitious export…
October Pharma (OP) S.A.E is an Egyptian enterprise molded by global aspirations. This has always demanded a preparedness and long- term organizational vision that can encompass the turbulence’s and paradoxes of shifting terms and terrain’s of business.
October Pharma (OP) is producing different pharmaceutical dosage forms of products under cGMP rules & regulations:
Solid (tablets, capsules & powder)
Liquid (syrup, drops, solution & spay)
Subcontract (Toll Out Manufacturing) for:
Soft Gelatin Capsules
Ampoule & Vial
Cream & Suppository
Powder
Contact
Piece #190, St. #25, 1st industrial zone,
6 October city. Cairo, Egypt
Tel: 38201832 / 38201652 / 38201329
Fax: +02 38201653
Email: info@octoberpharma.com
Ahmed Zaghloul, CEO of October Pharma, stresses the need for better infrastructure for biosimilars in Egypt to stay competitive on a global level. He also highlights October Pharma’s ambitious export…
“My primary concern is not the current economic situation, but rather the fact that there does not appear to be a clear vision for how Egypt can overcome these challenges…
MSD’s managing director for Egypt, Libya, Sudan and Yemen, Hazem Abdel Samie, shares his perspective on recent changes within the American multinational and explains why Egypt’s move from a predominantly…
Bayer’s Hatem Ismail introduces the company’s important work to help Egypt meet its ambitious Vision 2030 transformation goals; its significant footprint in the country across innovative pharmaceuticals, OTC drugs, and…
Roche Pharma General Manager in Egypt Mohamed Swilam shares his experience implementing a new operational model that is “challenging the status quo” of the pharma industry. He also explains the…
The CEO of Egypt’s Universal Health Insurance Authority (UHIA) Hossam Sadek outlines the country’s strategy to provide healthcare coverage for the entire population by 2030, explains how the system will…
Takeda Egypt’s Samy Khalil gives an overview of the company’s presence in the country and the fundamentals behind its double-digit growth there, provides his view of the healthcare transformation of…
Amgen’s country director for the ELI cluster (Egypt, Levant, and Iran), Ahmed Kishta, dives into the dynamics shaping the Egyptian market, Egypt’s Vision 2030 and how Amgen is contributing to…
Samir Khalil, executive director for the Pharmaceutical Research and Manufacturers of America (PhRMA) Middle East and Africa, touts the USD 1.1 trillion that its member companies have invested in R&D…
The head of the Pharmaceutical Chamber of the Federation of Egyptian Industries, Gamal El-Leithy, shares his view on the positive developments driving the growth of Egypt’s pharma market, including the…
The head of the Egyptian Unified Procurement Authority (UPA), Major General Doctor Bahaa El Din Zeidan, outlines the agency’s view on tenders, emphasizing their vision to secure the highest quality…
Egypt’s largest pharmaceutical manufacturer by units, EIPICO, plans to diversify its production capacity by building the country’s first biological & biosimilar production plant. Not only that, the company is leading…
The chairman of EIPICO – Egypt’s largest pharma company by units –, Dr Ahmed Kelani, outlines the company’s ambitious growth strategy, which includes the construction of the first biological &…
Four years after Egypt enacted a new universal health law, the country’s pharmaceutical market has consolidated itself as the fastest growing in the Middle East and Africa, far outpacing Saudi…
See our Cookie Privacy Policy Here
